Navigation Links
Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Date:10/9/2007

Phase 2 Drug Candidate Protects the Ocular Surface Following Exposure to

Controlled Adverse Environment, Reduces Dry Eye Symptoms

LAGUNA HILLS, Calif., Oct. 9 /PRNewswire/ -- Alacrity Biosciences today announced that its dry eye treatment, ALTY-0501, demonstrated statistically significant advantages over vehicle in its ability to control signs and symptoms of dry eye in a Phase 2 study.

The Phase 2 study utilized the controlled adverse environment (CAE) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. Patients were randomized to receive ALTY-0501 or its vehicle four times each day over the course of a 56 day study.

Patients who received ALTY-0501 demonstrated statistically significantly lower scores following CAE exposure for fluorescein staining of the total cornea-a measure of damage to the ocular surface-than those who received vehicle (p < 0.05) on day 28. Statistically significant differences from vehicle were also observed with total corneal and conjunctival staining (p < 0.05), superior corneal staining (p < 0.001) and nasal conjunctival staining (p < 0.05).

ALTY-0501 also demonstrated statistically significant advantages compared to vehicle in the patient diary scores measuring the severity of dry eye symptoms over the 56-day study period. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p < 0.0001), stinging (p < 0.0001), and grittiness (p < 0.0001) in the active treated group.

"We have strong evidence that ALTY-0501 can help control patient signs and symptoms by maintaining the epithelial barrier on the surface of the eye," said David F. Power, Alacrity's president and CEO. "We plan to discuss the Phase 2 data and confirm our Phase 2b/3 strategy with the FDA in the fourth quarter of 2007. Our in
'/>"/>

SOURCE Alacrity Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015   AMC Health ... will showcase advances in monitored care that are transforming ... ATA 2015 Conference, May 2-5 at the ... AMC Health will share information about how their ... to help transform and personalize healthcare delivery at Booth ...
(Date:4/27/2015)... -- The North America ... $4,211.2 million by 2019, at a CAGR of 5.0% from ... the North America ophthalmology surgery device ... It also provides a glimpse of the segmentation of this ... tables and figures. http://www.micromarketmonitor.com/market/north-america-ophthalmology-surgery-devices-9102894245.html ...
(Date:4/27/2015)... 27, 2015 PAML announced today that ... with Axela, Inc. to develop multiplex assays focused ... one of the nation,s leading medical reference laboratories, ... protein analysis for clinical diagnostics. ... and assay development serves as the foundation for ...
Breaking Medicine Technology:AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 3PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2
... SAN DIEGO, Nov. 2, 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Suisse 2011 Healthcare Conference in Phoenix on Wednesday, November 9, ... M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
... Inc. (NASDAQ: IPHS ), the leading North ... beverage, pharmaceutical, oral care and industrial end markets, today ... and completed the acquisition of Kelatron Corporation. ... manufacturer of bioactive mineral nutrients. For over 30 years, ...
Cached Medicine Technology:Innophos Holdings, Inc. Announces Acquisition of Kelatron Corporation 2
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
(Date:4/27/2015)... Ticket Down is a reputable source ... Valley Music Theatre and the Isleta Amphitheater. ... Mexico area can celebrate because their favorite performer will ... Buffett will be performing alongside legendary performers, Huey Lewis ... during the summer and fall months of 2015 are ...
(Date:4/27/2015)... 2015 The global coagulation analyzers ... CAGR in developed countries; however, it is expected ... as China, India and Brazil in the next ... is driven by factors such as increasing adoption ... of high-throughput hemostasis analyzers, developments in high-sensitivity point-of-care ...
(Date:4/27/2015)... 2015 Volpara Solutions today announced ... the Society of Breast Imaging’s SBI/ACR Breast Imaging ... Booth #214). VolparaDensity, the first breast density ... breast tomosynthesis datasets from multiple manufacturers, is already ... and worldwide. , The latest version ...
(Date:4/27/2015)... Puroast Coffee has signed on to sponsor the ... BattleFrog OCR is a series of rigorous courses designed by ... the training that Seals undergo, as well as provide a ... to sponsor the BattleFrog events this year,” says Puroast CEO ... well-suited to give people throughout the country the chance to ...
Breaking Medicine News(10 mins):Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 2Health News:Volpara Solutions Releases VolparaDensity 3.1 for Use with Tomosynthesis Systems from Multiple Manufacturers at SBI 3Health News:Puroast Coffee on Tour with BattleFrog 2
... Reporter , MONDAY, April 18 (HealthDay News) -- New ... stay clear of AIDS longer if they start drug ... However, starting treatment earlier, compared to waiting, didn,t ... benefit in terms of preventing death" by prescribing the ...
... , MONDAY, April 18 (HealthDay News) -- Patients with ... die after surgery, even after non-emergency procedures, a new study ... be used to revive someone who is clinically unresponsive and ... 18 and in the August print issue of the journal ...
... New research finds that older diabetics with better control of ... as heart attacks, amputation and kidney disease. However, ... sugar levels face a slightly higher chance of dying than ... normal range. Researchers tracked more than 70,000 people with ...
... , MONDAY, April 18 (HealthDay News) -- Infection with ... many college students -- and little exposure to sunlight may ... a new study suggests. "MS is more common at ... researcher, Dr. George C. Ebers, of the University of Oxford ...
... ovarian cancer (HGSOC), the fifth-deadliest cancer among American women, ... fallopian tube malignancy masquerading as an ovarian one. While ... tubes has so far been only circumstantial, a new ... connection, a finding that could aid in the development ...
... Ill. Nearly 800 dental sleep medicine professionals from ... Meeting of the American Academy of Dental Sleep Medicine ... at the Hilton Minneapolis in Minneapolis, Minn. The meeting ... 25th Anniversary Meeting of the Associated Professional Sleep Societies. ...
Cached Medicine News:Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 2Health News:Starting HIV Drugs Earlier May Delay AIDS But Not Death 3Health News:People With DNR Orders More Apt to Die After Any Surgery 2Health News:Low Glucose Levels May Raise Death Risk Among Older People 2Health News:Can Common Virus, Lack of Sunlight Boost MS Risk? 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 2Health News:New scientific model tracks form of ovarian cancer to origins in fallopian tube 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: